Premium
Pharmacological and toxicological study of two analogues of amphotericin by using in vitro models
Author(s) -
LeónBuitimea Angel,
MoralesNava Rosmarbel,
FernándezZertuche Mario,
OrtegaBlake Ivan,
ReyesEsparza Jorge,
RodriguezFragoso Lourdes
Publication year - 2010
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.24.1_supplement.964.1
Subject(s) - candida albicans , amphotericin b , in vitro , pharmacology , corpus albicans , cell cycle , cell , viability assay , flow cytometry , microbiology and biotechnology , cell growth , biology , chemistry , immunology , biochemistry , antifungal
The aim of present study was to investigate the pharmacological and toxicological effects of amphotericin B and two analogues (AMB0‐A1 and AMB0‐A2) on in vitro models. For study we used epithelial kidney cells in order to evaluate changes in cell proliferation, cell cycle and identify the cell death. Cells were treated with AmB or analogues in three concentrations (1, 10 and 100μM). The hemolytic activity was tested in human red blood cells. For pharmacological study we cultured C. albicans. Yeasts were treated with AmB or analogues and the inhibitory effect was analyzed by using Flow Citometry. Both did not affect renal cells and red blood cells at 1 and 10μM after 24h treatment. However, they reduced cell viability (17 y 11% respectively, (p<0.05) as compared with AmB. The AmB and analogues induced changes in cell proliferation, cell cycle and cell death in a dose‐dependent manner. Both analogues showed similar anti‐mycotic effect against C. albicans yeasts, at 10 and 100 μM after 24h treatment, p< 0.05. In conclusion, both analogues displayed anti‐mycotic activity against Candida albicans and had less toxic effects than AmB. Analogues might have a potential use as a new alternative in the treatment of the systemic fungal infections and/or as a base for further studies.